SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-046032
Filing Date
2022-02-18
Accepted
2022-02-18 08:06:02
Documents
12
Period of Report
2022-02-18
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d325651d8k.htm   iXBRL 8-K 25522
  Complete submission text file 0001193125-22-046032.txt   147569

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atra-20220218.xsd EX-101.SCH 2861
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20220218_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20220218_pre.xml EX-101.PRE 11265
6 EXTRACTED XBRL INSTANCE DOCUMENT d325651d8k_htm.xml XML 3370
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 22650882
SIC: 2836 Biological Products, (No Diagnostic Substances)